INSR and cancer: Insulin is a growth factor, and the possibility of reducing the daily dosage per kilogram could, in the long term, reduce the risks linked to its mitotic effect on cells and anabolic effects on tissues, reducing the activation of the insulin receptor and the post-receptor pathways, which may have a stronger mitogenic potency on cancer cells [70].